SLC5A2 and hydrops fetalis: As SGLT2 inhibitors improve morbidity and survival in HF patients by direct cardioprotective, antifibrotic, and anti-inflammatory effects and ATTR-CA is underdiagnosed in the HF population, it remains a possibility that SGLT2 inhibitors are well tolerated, improve morbidity as well as survival, and facilitate reverse remodeling in ATTR-CA [28].